The current drug treatment recommended in DKD is primarily based on angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) to block the renin–angiotensin–aldosterone system (RAAS) but also on sodium/glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, mineralocorticoid receptor antagonists, and endothelin antagonists, with effects both on glycemic control and RAAS blockade. This evidence concerns the gene SLC5A2 and diabetic kidney disease.